Premaitha Health PLC Second tranche of warrants issued to Thermo Fisher (2363B)
March 31 2017 - 11:00AM
UK Regulatory
TIDMNIPT
RNS Number : 2363B
Premaitha Health PLC
31 March 2017
Premaitha Health Plc
("Premaitha" or the "Company")
Second tranche of warrants issued to Thermo Fisher
Scientific
Manchester, UK - 31 March 2017 - Premaitha Health PLC (AIM:
NIPT), a leading international molecular diagnostics group focused
on prenatal testing, announces that it has issued the second
tranche of warrants to Thermo Fisher Scientific ("Thermo Fisher")
as part of the investment agreement extension announced on 23
September 2016 ("Agreement").
Under the terms of the Agreement, Premaitha agreed to issue a
second and final tranche of warrants for the equivalent of GBP2.0m
by 1 April 2017. The warrants issued ("2017 Warrants") are over
16,913,319 new ordinary shares in the Company exercisable at 11.825
pence, being a premium of 10% over the closing share price on 30
March 2017 (the last business day prior to issue of the 2017
Warrants).
-Ends-
For more information, please contact:
Premaitha Health PLC Tel: +44 (0)
Dr Stephen Little, Chief Executive 161 667 1053
Officer investors@premaitha.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)
Liam Murray / James Caithie 20 7213 0880
finnCap (Broker) Tel: +44 (0)
Adrian Hargrave / Scott Mathieson 20 7220 0500
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
Ben Simons / Fiona Henson / Antonia 20 7830 9700
Pollock
premaitha@vigocomms.com
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of fetal DNA - and estimates the risk of a fetus
being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJBMITMBIJBRR
(END) Dow Jones Newswires
March 31, 2017 11:00 ET (15:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024